| 2026-08-12 | Press release | Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors |
| 2026-08-12 | 8-K | Form 8-K, Item 5.02 |
| 2026-08-06 | Press release | Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference |
| 2026-08-06 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-30 | Press release | Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates |
| 2026-07-30 | Deck | Second-Quarter 2026 Financial Results Presentation |
| 2026-07-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-07-30 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-30 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-21 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-16 | Press release | Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on |
| 2026-07-13 | Press release | Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio |
| 2026-07-06 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-22 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-17 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-04 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-03 | Press release | Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 |
| 2026-05-27 | Press release | Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with |
| 2026-05-21 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-20 | Press release | Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Mark |
| 2026-05-07 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-06 | Deck | First-Quarter 2026 Financial Results Presentation |
| 2026-05-06 | Press release | Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Press release | Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline |
| 2026-04-28 | Proxy | Definitive proxy statement |
| 2026-04-28 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-22 | Press release | Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 |
| 2026-04-21 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-07 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-19 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-05 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 2026-02-24 | Press release | Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference |
| 2026-02-20 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-19 | Deck | Fourth-Quarter 2025 Financial Results Presentation |
| 2026-02-19 | Press release | Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results |
| 2026-02-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-17 | Press release | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |